PureTech Announces Annual Results for Year Ended December 31, 2020
By
Staff
2 seconds ago
Strong capital base and cash runway extended into the first quarter of 2025, with PureTech level cash and cash equivalents of $443.4 million as of March 31, 2021
1 ($349.4 million as of December 31, 2020
2) and consolidated cash and cash equivalents of $486.5 million as of March 31, 2021
3 ($403.9 million as of December 31, 2020
4)
Advancement of Wholly Owned Pipeline with four clinical trial initiations and one successful readout, with three clinical trials ongoing
Significant milestones across PureTech’s Founded Entities including one FDA Clearance for Marketing, two European Marketing Authorizations, initiation of a Phase 3 program, $247.8 million raised in 2020
5 and $473.2 million raised in the 2021 post-period
Press release content from Business Wire. The AP news staff was not involved in its creation.
PureTech Founded Entity Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to its Board of Directors
January 14, 2021 GMT
BOSTON (BUSINESS WIRE) Jan 14, 2021
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”) is pleased to note that its Founded Entity, Follica, today announced the appointment of two veteran biotech executives to its Board of Directors.
ADVERTISEMENT
Follica announced the appointment of two veteran biotech executives to its Board of Directors. Tom Wiggans, former CEO of Dermira, joins as Executive Chairman, and Michael Davin, former CEO of Cynosure, joins as an independent member.
Bringing a depth of expertise in product registration, commercial & business developmentTom Wiggans, former CEO of Dermira, joins as Executive Chairman Michael Davin, former CEO of Cynosure, joins Board of DirectorsBOSTON (BUSINESS WIRE) PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”).